Related Experiment Video

Updated: May 9, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype

Jay A Friedman1, Stephanie C Wise, Michael Hu

  • 1Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD.

Translational Oncology
|August 3, 2013
PubMed

Insights

Heat shock protein 90 (HSP90) inhibitor SNX5422/2112 shows broad anticancer activity in head and neck squamous cell carcinomas (HNSCC). This HSP90 inhibitor effectively targets key cancer pathways and enhances responses to chemotherapy and radiotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Heat shock protein 90 (HSP90) is a crucial chaperone protein implicated in the oncogenic and therapeutic resistance pathways of epithelial cancers, particularly head and neck squamous cell carcinomas (HNSCCs).
  • Overexpression of HSP90 in HNSCC contributes to cancer progression and treatment failure.

Purpose of the Study:

  • To characterize the molecular, cellular, and preclinical activity of the HSP90 inhibitor SNX5422/2112 in HNSCC models.
  • To evaluate the potential of SNX5422/2112 as a therapeutic agent, alone and in combination with standard treatments, for HNSCC.

Main Methods:

  • In vitro studies involving HNSCC cell lines with varying TP53 status to assess proliferation, cell cycle, cytotoxicity, chemosensitivity, and radiosensitivity.
  • Analysis of signaling pathway modulation, including key oncogenes, angiogenic cytokines, and downstream reporter genes.
  • In vivo studies using a xenograft model of HNSCC to evaluate the efficacy of SNX5422/2112 in inhibiting tumor growth, angiogenesis, and promoting apoptosis.

Main Results:

  • SNX2112 demonstrated significant inhibition of HNSCC proliferation, induced G2/M cell cycle arrest, and enhanced sensitivity to chemotherapy and radiotherapy at nanomolar concentrations.
  • The inhibitor effectively modulated key signaling pathways, including EGFR, c-MET, AKT, ERK, IKK, and STAT3, and restored TP53 expression and function.
  • SNX5422/2112 exhibited combinatorial activity with paclitaxel and cisplatin in TP53-wild-type and TP53-mutant HNSCC, respectively.
  • SNX5422, the prodrug, showed similar effects in vitro and inhibited tumor growth, angiogenesis, and tumorigenesis in vivo.

Conclusions:

  • HSP90 inhibitor SNX5422/2112 broadly targets multiple signaling nodes in HNSCC, impacting the malignant phenotype.
  • SNX5422/2112 shows promise as a therapeutic agent for HNSCC, particularly in combination with chemotherapy (paclitaxel, cisplatin) and radiotherapy.
  • Further investigation of SNX5422/2112 in HNSCC patients with diverse TP53 statuses is warranted.

More Related Videos

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma08:59

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Published on: January 5, 2017

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...